Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
27 September 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Lupin Ltd (Pharmaceuticals - Indian - Bulk Drugs)

Last Price 1,006.00
Net Changes 14.30
Volume 1967659
Prev Close 991.70
1,006.00 14.30 (1.44%)
Date: Sep 26,2017 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs


Chart

Stock Price Details

Market Statistics

Open Price 997.55 Div Yield (%) 0.74
Buy (Size) 0.00(×0) Eps(Rs) 53.47
Sell (Size) 0.00(×0) Book Value(Rs) 327.144158
Buy Quantity 0 Market Cap(Rs.Cr) 45412.39
Sell Quantity 0 Face Value(Rs) 2
Today's High 1013.1 Market Lot 1
Today's Low 993.55 AGM Date Aug
52-Week High 1572.25 Book Closure Date Jul/Aug
52-Week Low 920 ISIN No. INE326A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 803800 0.18
Indian (Promoter & Group) 210141313 46.52
Total of Promoter 210945113 46.70
Non Promoter (Institution) 183713396 40.67
Non Promoter (Non-Institution) 57065408 12.63
Total Non Promoter 240778804 53.30
Total Promoter & Non Promoter 451723917 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 451723917 100.00

Company News

25-Sep-2017  Lupin allots 40,988 equity shares
Lupin allots 40,988 equity shares

Lupin has allotted 40988 equity shares under ESOP on 25 September 2017. With this allotment, the paid up capital of the Company has increased to Rs 90.37 crore consisting of 45,18,38,126 equity shares of Rs 2 each.
25-Sep-2017  Lupin receives final approval for generic Clobex® Lotion, 0.05%
Lupin receives final approval for generic Clobex® Lotion, 0.05%

Lupin has received final approval from the USFDA to market Clobetasol Propionate Lotion, 0.05%, the generic version of Galderma Laboratories' Clobex® Lotion, 0.05%.
18-Sep-2017  Lupin appoints Chief Corporate Development Officer
Lupin appoints Chief Corporate Development Officer

Lupin announced the appointment of Jim Loerop as Chief Corporate Development Officer of the Company
18-Sep-2017  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated September 18, 2017, titled 'Lupin appoints Jim Loerop as Chief Corporate Development Officer'.
13-Sep-2017  Lupin receives final approval for generic Flagyl Tablets
Lupin receives final approval for generic Flagyl Tablets

Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the USFDA to market a generic version of G D Searle LLC's Flagyl Tablets, 250 mg and 500 mg.
13-Sep-2017  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated September 13, 2017, titled 'Lupin receives FDA approval for generic Flagyl. Tablets'.
11-Sep-2017  Lupin receives final approval for generic Vibra-Tabs Tablet
Lupin receives final approval for generic Vibra-Tabs Tablet

Lupin has received final approved for its Doxycycline Hyclate Tablet USP, 100 mg from USFDA to market the generic version of Pfizer Inc.'s Vibra-Tabs, 100 mg.
11-Sep-2017  Lupin heads north after FDA nod for generic tablet
Lupin heads north after FDA nod for generic tablet

The announcement was made during market hours today, 11 September 2017.

Meanwhile, the S&P BSE Sensex was up 234.70 points or 0.74% at 31,922.22.

On the BSE, 2.71 lakh shares were traded on the counter so far as against the average daily volumes of 1.78 lakh shares in the past one quarter. The stock had hit a high of Rs 982.65 and a low of Rs 969 so far during the day. The stock had hit a 52-week high of Rs 1,590 on 9 September 2016 and a 52-week low of Rs 920 on 21 August 2017.

The stock had outperformed the market over the past one month till 8 September 2017, sliding 0.65% compared with the Sensex's 1.02% fall. The stock had, however, underperformed the market over the past one quarter, sliding 17.16% as against the Sensex's 1.52% rise. The scrip had also underperformed the market over the past one year, declining 38.7% as against the Sensex's 9.1% rise.

The large-cap company has equity capital of Rs 90.36 crore. Face value per share is Rs 2.

Lupin said it has received final approval for its Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s Vibra-Tabs, 100 mg.

Lupin's Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.'s Vibra-Tabs, 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablet USP, 100 mg had US sales of $149.9 million (IMS MAT June 2017).

Lupin's consolidated net profit fell 59.4% to Rs 358.06 crore on 12.3% decline in net sales to Rs 3806.83 crore in Q1 June 2017 over Q1 June 2016.

Lupin is a transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

11-Sep-2017  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated September 11, 2017, titled 'Lupin receives FDA approval for generic Vibra-Tabs. Tablet'.
07-Sep-2017  Lupin Limited - Investor Presentation
Lupin Limited - Investor Presentation

Lupin Limited has informed the Exchange regarding Investor Presentation
Incorporation Year 1983 
Registered Office Kalpataru Inspire 3rd Floor,Off Western Exp HW Santacruz-E,
Mumbai,
Maharashtra-400055
Telephone 91-22-6640 2323 
Fax 91-22-6640 8131 
Chairman D B Gupta
Managing Director Nilesh Gupta
Company Secretary R V Satam 
Auditor B S R & Co LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Lupin Ltd
Kalpataru Inspire,3rd Floor,Santacruz (East),Mumbai - 400 055 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS